Economy
Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Publication and source
PublicationSanalda Haber
SourceCNBC
Published
CategoryEconomy
Summary from the source publisher’s news feed.